FDA Approves New Drug Eylea for Blindness

Regeneron Pharmaceuticals Inc.'s drug Eylea, an injection designed to treat neovascular or 'wet' age-related macular degeneration.

Regeneron Pharmaceuticals Inc.'s drug Eylea, an injection designed to treat neovascular or 'wet' age-related macular degeneration, a leading cause of blindness in older people has been approved by the FDA. Eylea is the first competitor to Basel, Switzerland-based Roche’s Lucentis. Its approval boosts the number of Regeneron's marketable products to two.

Regeneron's CEO says Eylea will be available to patients within days. Eylea will be injected every 8-weeks, half as often as Lucentis. It is expected to capture 16% of market from Lucentis.

Age Related Macular Degeneration (AMD) - Causes, Symptoms, Diagnosis, Treatment & Prevention
Age related macular degeneration is a disease of the elderly, wherein the macula or the central part of the retina gets affected, leading to loss of vision.

Eylea may cost $1,950 per injection. The drug will hit peak sales of $1.1 billion by 2021.

Source-Medindia

Foods that Give You Sparkling Eyes
Food not only sustains us but the kind and quality of food determines the state of your health, which includes your eyes. Let us see which foods can bring a sparkle to your eyes!

Research 'Extraordinaire' To Restore Vision
UK scientists have discovered a treatment for blindness in mice by employing stem cell transplants

Decline in Human Donor Eyes Affects Vision Research
A decline in the number of human donor eyes provided for ophthalmology research by U.S. eye banks may have a negative impact on clinical ophthalmology